In a world where “precision” is usually just a marketing buzzword, Jupiter Endovascular decided to make it literal. The Menlo Park crew isn’t playing around, they’re bringing surgical-level control to catheter-based therapies, and investors just lined up to prove it. The company closed an oversubscribed Series B north of $40M, led by Sonder Capital with strong support from Senvest Management, LB Investment, and a new strategic corporate investor.
That kind of demand doesn’t happen by accident. It happens when you’ve got something no one else can replicate. Jupiter’s Transforming Fixation (TFX) platform isn’t just another acronym in a crowded medtech field, it’s the key that lets flexible catheters morph into stable, controlled instruments once they reach their target. Think about that for a second: navigating through the body’s most chaotic highways, then locking in with the precision of a surgeon’s hand. It’s the kind of leap that turns “impossible” into standard practice.
The brains behind it? Founder Alex Tilson, the inventor of the Endoportal Control platform and serial innovator who already built Neptune Medical before spinning out Jupiter. At the operational helm sits Carl J. St. Bernard, CEO and 30+ year medtech veteran whose resume reads like a tour through the industry’s greatest hits, GE Healthcare, Johnson & Johnson Vision, CeloNova, Alta Biomaterials. Backing him is Fred Ong, CFO and finance architect known for scaling healthtech companies from the inside out. And with Deborah Kilpatrick, Kate Garrett, Jay Watkins, and Fred Moll from Sonder Capital on the board, this isn’t just leadership, it’s a brain trust.
The timing couldn’t be sharper. Jupiter just landed FDA 510(k) clearance for its Vertex Catheter system with TFX, clearing the way for commercialization in the $3B pulmonary embolism device market. The SPIRARE I first-in-human trial already showed results worth presenting at TCT 2025, and SPIRARE II is now enrolling 145 subjects across the U.S. & Europe. It’s textbook momentum for a company barely a year out of stealth.
Series B funds will push SPIRARE II to completion, ramp commercial launch of Vertex, and fuel new TFX applications across peripheral and neurovascular therapies. The mission isn’t to chase headlines, it’s to build a platform that transforms how endovascular procedures are done, period. Surgical precision through a needle puncture is no longer science fiction, it’s Menlo Park hardware in real time.
